Pfizer Reveals Details of Wyeth-Infused Corporate Structure

Pfizer has announced details of what it will look like following the merger with Wyeth, saying that it aims to keep most key Wyeth execs as heads of a new BioTherapeutics Research Group. The small-molecule group will be labelled, creatively, the PharmaTherapeutics Research Group, and will be run by Martin Mackay, who now oversees PGRD. Here's the official release with more.